Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Laurent MAUVIEUX, MD, PhD

Saïd CHAYER, PhD, HDR

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL

Leukemic Phase of ALCL

Leukemic Phase of ALK+ Anaplastic Lymphoma in Real-life Practice: Experience of a University Clinical Hematology Laboratory

University Hospital, Strasbourg, France

Lymphoma, Non-Hodgkin

Lymphoma, Large-Cell, Anaplastic

Anaplastic Large Cell Lymphoma

Sun Xiao-Fei

Zhen Zi-Jun

Sun Xiaofei

With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Studies in Germany and the United States have shown that pathological types of systemic anaplastic large cell lymphoma (ALCL) in children and adolescents, minimal disseminated disease (MDD) in peripheral blood or bone marrow and minimal residual disease (MRD) are significantly associated with prognosis, suggesting that these factors need to be combined in risk stratification of ALCL patients. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. We adjusted the original NHL-BFM-90/95 regimen, mainly in the aspects of clinical staging, efficacy evaluation, risk stratification and treatment regimen，etc.

Research purpose:

1. To study the efficacy and safety of SCCCG-ALCL-2017 regimen in children with systemic ALK-positive anaplastic large cell lymphoma.
2. To explore the correlation between MDD or MRD in peripheral blood or bone marrow and the treat response and survival.
3. To explore the feasibility of risk stratification combined with adverse pathological types, dangerous organ invasion and MDD.
4. To investigate the effect of vinblastine maintenance chemotherapy on survival of patients with MRD-positive in peripheral blood after treatment.

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL

A Prospective Multicenters Clinical Cohort Study of the Efficacy and Safety of Stratified Risk Factors for Treatment of Chinese Children With Systemic ALK-positive Anaplastic Large Cell Lymphoma

EFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease or relapse, treatment related death, death of any other cause or diagnosis of secondary malignancies

OS is defined as time from start of treatment/randomization up to death of any

RFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease, or relapse.

Complete response, partial remission, objective effect, stable disease or progressive disease

Rate of patients with acute toxicity defined as grade III/IV/V AE

Study title	NCT ID	Conditions	Eligibility	Organization
Leukemic Phase of ALCL	NCT04908059	Anaplastic Lymp...	9 Years -	University Hospital, Strasbourg, France
Leukemic Phase of ALCL	NCT04908059	Anaplastic Lymp...	9 Years -	University Hospital, Strasbourg, France
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL	NCT03971305	MRD MDD Lymphoma, Nonho... Anaplastic Lymp... Pediatric Cance...	1 Year - 18 Years	Sun Yat-sen University
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL	NCT03971305	MRD MDD Lymphoma, Nonho... Anaplastic Lymp... Pediatric Cance...	1 Year - 18 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for anaplastic lymphoma